TQB 3720
Alternative Names: TQB-3720Latest Information Update: 28 Apr 2026
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics
- Mechanism of Action Androgen receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 28 Apr 2026 No recent reports of development identified for phase-I development in Prostate-cancer(Hormone refractory, Metastatic disease, Second-line therapy or greater) in China (PO, Tablet)
- 30 Dec 2025 Chia Tai Tianqing Pharmaceutical terminates a phase I trial in Prostate cancer (Hormone-refractory, Metastatic disease, Second-line therapy or greater) in China (PO, Tablet), due to sponsor request, and premature closure was not prompted by any safety or efficacy concerns (NCT04853498)